Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma

August 2015
Oncology Letters;Aug2015, Vol. 10 Issue 2, p879
Academic Journal
The aim of the present study was to investigate the effect of lymphokine-activated killer (LAK) cells, which received low-dose ionizing radiation, on the treatment of osteosarcoma in rats. The cultured UMR-106 cells were inoculated under the anterior chest skin of 24 rats to establish an osteosarcoma model. In addition, the LAK cells from 24 mice were exposed to doses of 0 (control group), 0.65 or 3.25 mGy X-ray radiation. The tritiated thymidine (3H-TdR) release method and Winn assay were performed to determine the anti-tumor effects of the LAK cells. The proliferation of the mouse LAK cells treated with 3.25 mGy radiation was significantly higher than that for those treated with 0 or 0.65 mGy radiation, which suggested that low-dose ionizing radiation stimulates the proliferation of LAK cells. The tumor-bearing rats were divided into three groups and injected with LAK cells that had already received 0, 0.65 or 3.25 mGy radiation. The mean survival time of the 3.25-mGy group was longer than that of the 0- and 0.65-mGy groups. After 30 days, tumors with weights of ~6.25 and 2.0 g were identified in the rats of the 0- and 0.65-mGy groups, respectively. However, tumor proliferation was not detectable in the rats of the 3.25-mGy radiation group. Therefore, low-dose ionizing radiation effectively kills osteosarcoma cells in rats by stimulating the proliferation and enhancing the cytotoxicity of LAK cells.


Related Articles

  • Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. ZONG-GANG XIE; YEXIE; QI-RONG DONG // Oncology Letters;2013, Vol. 6 Issue 5, p1465 

    It has been well documented that the inhibition of the mammalian target of rapamycin (mTOR) induces autophagy in proliferative cells. Therefore, mTOR inhibitors have been proposed for the treatment of cancer. As autophagy plays significant roles in tumor cell survival, the present study aimed to...

  • The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse. Quist, T; Jin, H; Zhu, J-F; Smith-Fry, K; Capecchi, M R; Jones, K B // Oncogene;8/6/2015, Vol. 34 Issue 32, p4278 

    Osteosarcomas remain an enigmatic group of malignancies that share in common the presence of transformed cells producing osteoid matrix, even if these cells comprise a minority of the tumor volume. The differentiation state of osteosarcomas has therefore become a topic of interest and challenge...

  • Downregulation of microRNA-210 inhibits osteosarcoma growth in vitro and in vivo. CHANGJIAN LIU; XIN TANG // Molecular Medicine Reports;2015, Vol. 12 Issue 3, p3674 

    MicroRNA-210 (miR-210), the master hypoxamir, has various roles in the development of certain cancer types. It has been reported that miR-210 expression was upregulated in patients with osteosarcoma (OS). However, little is known regarding its role in the development of human OS. In the present...

  • Saurolactam Inhibits Proliferation, Migration, and Invasion of Human Osteosarcoma Cells. Li, Zhengwei; Liu, Hui; Li, Baizhi; Zhang, Yanzhe; Piao, Chengdong // Cell Biochemistry & Biophysics;Jul2015, Vol. 72 Issue 3, p719 

    Osteosarcoma is a common type of malignant bone tumor with features of osteoid formation or osteolytic lesions of bone. New therapeutic approaches are urgently needed since it lacks response to chemotherapeutic treatments. Saurolactam, a natural compound isolated from the aerial portions of...

  • MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells. Ning Duan; Xiaojing Hu; Xiaowei Yang; Huiguang Cheng; Wentao Zhang // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 9, p10250 

    MicroRNAs (miRNAs) are endogenous, non-coding, small RNAs, which play a critical role in regulating varieties of the biological and pathologic processes. Several reports have indicated that mi-370 acts as a tumor suppressor in varieties of tumors. However, the roles of mi-370 in osteosarcoma...

  • Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Chang-ye Zou; Jin Wang; Jing-nan Shen; Gang Huang; Song Jin; Jun-qiang Yin; Qian-chen Guo; Hao-miao Li; Lan Luo; Meng Zhang; Long-juan Zhang // Acta Pharmacologica Sinica;Mar2008, Vol. 29 Issue 3, p325 

    Aim: To characterize and compare the different biological behaviors of 2 novel human osteosarcoma cell lines, Zos and Zos-M, established respectively from the primary tumor and the skip metastasis of an osteosarcoma patient. Methods: In vitro studies included morphological observations,...

  • Resveratrol inhibits canonical Wnt signaling in human MG-63 osteosarcoma cells. YONGGEN ZOU; JIEXIANG YANG; DIANMING JIANG // Molecular Medicine Reports;2015, Vol. 12 Issue 5, p7221 

    In the last 30 years, the 5-year-survival rate of patients with osteosarcoma has not improved as a result of the low prevalence and large tumor heterogeneity. Therefore, the development of novel drugs for the treatment of osteosarcoma is urgently required. The present study aimed to identify...

  • miR-214 promotes osteosarcoma tumor growth and metastasis by decreasing the expression of PTEN. CHUN-JIE LIU; KUN-LUN YU; GUO-LI LIU; DE-HU TIAN // Molecular Medicine Reports;2015, Vol. 12 Issue 4, p6261 

    MicroRNAs (miRNAs) are a class of small non-coding RNAs, which function as critical gene regulators by targeting mRNAs for translational repression or degradation, and they are essential in cancer development and progression. Several previous studies have indicated that abnormal expression of...

  • MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate. LIANGDONG JIANG; AIYONG HE; XIAOJIE HE; CHENG TAO // Oncology Letters;Dec2015, Vol. 10 Issue 6, p3769 

    The establishment of novel chemotherapy drugs for osteosarcoma is urgently required, and the mechanisms and effects of cisplatin (DDP) and methotrexate (MTX) in the current treatment of osteosarcoma have not been fully elucidated. The present study aimed to observe the effect of DDP, MTX and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics